Multiple Myeloma Clinical Trial
Official title:
A Phase III Study to Determine the Role of Ixazomib as an Augmented Conditioning Therapy in Salvage Autologous Stem Cell Transplant (ASCT) and as a Post-ASCT Consolidation and Maintenance Strategy in Patients With Relapsed Multiple Myeloma
Study design: Randomised, controlled, multi-centre, open-label, phase III trial (with a
single intervention registration phase).
Primary Objectives
The primary objectives of this study are to determine:
- The impact on Depth of Response (DoR: less than VGPR versus VGPR or better) when salvage
ASCT conditioning is augmented by the addition of a proteasome inhibitor
- The influence of a consolidation and maintenance strategy on the Durability of Response
(DuR:PFS)
Secondary objectives
The secondary objectives of this study are to determine:
- Overall survival
- Time to disease progression
- The overall response rate following ixazomib, thalidomide and dexamethasone (ITD)
re-induction
- Time to next treatment
- Progression-free survival 2 (PFS2)
- Duration of response
- Minimal Residual Disease (MRD) negative rate post re-induction, post-ASCT and conversion
after ITD consolidation
- Engraftment kinetics
- Toxicity and safety
- Quality of life (QoL)
Participant population (refer to protocol section 9 for a full list of eligibility criteria).
- Relapsed MM (with measurable disease by IMWG criteria) previously treated with ASCT
- First progressive disease (PD) at least 12 months since first ASCT, requiring therapy.
- ECOG Performance Status 0-2
- Aged at least 18 years
- Adequate full blood count and renal, hepatobiliary, pulmonary and cardiac function
- Written informed consent
Interventions: All participants will be registered at trial entry and will receive
re-induction therapy with 4-6, 28-day cycles of ixazomib, thalidomide and dexamethasone
(ITD), in order to reach maximum response. Participants who achieve at least stable disease
(SD) will be randomised on a 1:1 basis to receive either conventional ASCT (ASCTCon), using
melphalan, or augmented ASCT (ASCTAug), using melphalan with ixazomib. All participants
achieving or maintaining a minimal response (MR) or better following trial ASCT will undergo
a second randomisation to consolidation and maintenance or no further treatment. Participants
randomised to consolidation and maintenance will receive treatment as follows: consolidation
with 2 cycles of ITD and maintenance with ixazomib until disease progression.
Number of participants: 406 participants will be registered into the trial to allow 284
participants to be randomised at the first randomisation (R1) and 248 participants to be
randomised at the second randomisation (R2).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
| Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
| Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
| Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
| Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
| Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |